← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Thermo Fisher Scientific TMO $249B	2,267	-15	-0.7%	$175B
2	2 Danaher DHR $158B	2,031	+19	+0.9%	$148B
3	3 Novartis NVS $279B	1,088	-53	-5%	$13.7B
4	4 Regeneron Pharmaceuticals REGN $80.1B	1,080	+16	+2%	$64B
5	5 Agilent Technologies A $49.1B	898	+12	+1%	$31.3B
6	6 Illumina ILMN $41B	897	-14	-2%	$26.9B
7	7 Charles River Laboratories CRL $14.4B	582	-45	-7%	$9.91B
8	8 Revvity RVTY $17B	548	-36	-6%	$13.1B
9	9 DELISTED CATALENT, INC. CTLT	506	-38	-7%	$13.2B
10	10 Alnylam Pharmaceuticals ALNY $30B	497	+74	+17%	$26.7B
11	11 CRISPR Therapeutics CRSP $4.86B	435	0	0%	$3.7B
12	12 Sarepta Therapeutics SRPT $1.78B	376	+44	+13%	$8.65B
13	13 Ionis Pharmaceuticals IONS $7.1B	350	0	0%	$5.59B
14	14 Azenta AZTA $1.63B	341	-31	-8%	$3.17B
15	15 Guardant Health GH $21.9B	328	-4	-1%	$5.04B
16	16 Intellia Therapeutics NTLA $1.6B	321	+20	+7%	$3.81B
17	17 ARK Genomic Revolution ETF ARKG $2.05B	312	-22	-7%	$715M
18	18 Qiagen QGEN $9.41B	296	+8	+3%	$5.73B
19	NVTA 19 DELISTED Invitae Corporation NVTA	284	-2	-0.7%	$461M
20	20 Bruker BRKR $8.47B	280	-16	-5%	$5.58B
21	21 Ginkgo Bioworks DNA $776M	278	+18	+7%	$2.74B
22	22 Arrowhead Research ARWR $8.25B	277	-1	-0.4%	$2.35B
23	23 Editas Medicine EDIT $349M	265	+8	+3%	$592M
24	24 Fate Therapeutics FATE $232M	239	+6	+3%	$2.41B
25	25 Fulgent Genetics FLGT $578M	235	-27	-10%	$507M